Emerging Role of Nanomedicine in Cancer Theranostics: Targeted Drug Delivery, Mechanistic Insights, and Challenges in Clinical Translation
Новая роль наномедицины в тераностике рака: таргетная доставка лекарственных средств, механистические аспекты и проблемы клинической трансляции
2026-06-24
SCID: 54.1/sxt4y3gg
Discuss with AI
cancer theranosticsclinical translationdiagnostic imagingnanocarrierstargeted drug delivery
Figures from the paper
Abstract (AI)
Nanotechnology has become an innovative platform in modern medicine in which it has become possible to gain unprecedented control over drug delivery, diagnostic imaging and oncologic therapy at molecular and cellular levels. Systems of nanoparticles have unique benefits as compared to traditional therapeutics including improved bioavailability, site selectivity, controlled release dynamics, and reduced systemic toxicity. These characteristics are especially crucial in the field of oncology where localization of tumor and real-time monitoring of therapeutic procedures continue to be important clinical issues. This review is a critical review of recent advances in nanotechnology-based drug delivery platforms, diagnostic imaging modalities and cancer theranostics with a focus on mechanistic insights, material design strategies and translational advances. It talks of key classes of nanocarriers, approaches to target specificity and multifunctional theranostic designs, as well as approved nanomedicines and current clinical trials. Notably, the review outlines the major limitations that had hindered clinical translation, such as, biological barriers, toxicity issues and regulatory challenges. Combining the current evidence and identifying the gaps, the manuscript provides a holistic vision of the role played by nanotechnology in the evolution of precision medicine and outlines the future directions in which the designing and production of clinically applicable nanotherapeutic and diagnostic tools can be developed.
Key Findings
1
Clinical translation remains limited by biological barriers, toxicity concerns, and regulatory challenges despite approved nanomedicines and ongoing clinical trials.
2
Material design strategies and mechanistic understanding are identified as priorities for developing clinically applicable nanotherapeutic and diagnostic tools.
3
Nanoparticle systems can improve bioavailability, tumor-site selectivity, controlled drug release, and reduce systemic toxicity compared with traditional therapeutics.
4
Nanotechnology enables molecular- and cellular-level control over cancer drug delivery, diagnostic imaging, and therapy.
5
Recent nanomedicine advances integrate targeted delivery, diagnostic imaging, and multifunctional theranostic designs for real-time monitoring and precision oncology.
Research Object
nanotechnology-based cancer nanomedicine platforms, including nanoparticle drug-delivery systems, diagnostic imaging modalities, and theranostic systems
Research Subject
mechanistic principles, material-design strategies, therapeutic and diagnostic performance, targeting specificity, and barriers to clinical translation of cancer nanomedicine
Publication Details
Publication Date
2026-06-24
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest